(Q33389537)

26 July 2017

title

Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer (English)

1 reference

26 July 2017

Satoshi Igawa

1

1 reference

26 July 2017

Shinichiro Ryuge

2

1 reference

26 July 2017

Tomoya Fukui

3

1 reference

26 July 2017

Sakiko Otani

4

1 reference

26 July 2017

Yuka Kimura

5

1 reference

26 July 2017

Ken Katono

6

1 reference

26 July 2017

Akira Takakura

7

1 reference

26 July 2017

Masaru Kubota

8

1 reference

26 July 2017

Hisashi Mitsufuji

9

1 reference

26 July 2017

Masato Katagiri

10

1 reference

26 July 2017

Nobuo Yanase

11

1 reference

26 July 2017

Noriyuki Masuda

12

1 reference

26 July 2017

publication date

13 May 2010

1 reference

International Journal of Clinical Oncology

26 July 2017

published in

1 reference

26 July 2017

volume

15

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

447-452

1 reference

A statistical study of lung cancer in the annual of pathological autopsy cases in Japan, from 1958 to 1997, with reference to time trends of lung cancer in the world

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10147-010-0085-2

A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-010-0085-2

Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-010-0085-2

Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-010-0085-2

Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial

21 January 2018

1 reference

12 December 2020

Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs

1 reference

12 December 2020

Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

1 reference

12 December 2020

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

1 reference

12 December 2020

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

1 reference

12 December 2020

Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study

1 reference

12 December 2020

Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer

1 reference

12 December 2020

Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer.

1 reference

12 December 2020

Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer

1 reference

12 December 2020

A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer

1 reference

12 December 2020

Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer

1 reference

12 December 2020

Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study

1 reference

12 December 2020

10.1007/S10147-010-0085-2

Identifiers

DOI

1 reference

26 July 2017

1 reference